Clinical trials: DAPT(Dual Antiplatelet Therapy)
Clopidogrel, Poor Metabolism of, Carotid Stenosis
Multicentric Study on Clopidogrel Resistance in DAPT for CAS (MULTI-RESCLOSA)
Spontaneous prospective observational multicentre pharmacological study that aims to evaluate whether, from a statistical point of view, there is a significant difference between the use of Ticagrelor in "non-responders" patients…
- Trial name
- NCT05566301
- Testing
- Clopidogrel, Ticagrelor
- Where
- Italy
- Volunteers
- 1,140 people
- Sponsor
- IRCCS Policlinico S. Donato
Myocardial Infarction (MI)
Dual Antiplatelet Therapy Strategies After Acute Myocardial Infarction Undergoing PCI: Prasugrel vs Ticagrelor & 12 Months vs 1-3 Months
This study is testing different blood-thinning treatment strategies for people who have had a heart attack and were successfully treated with a coronary stent procedure (PCI).
- Trial name
- STREAMLINE (NCT07507500)
- Testing
- Prasugrel, Ticagrelor
- Where
- 5 sites in Ireland, Latvia and 3 more
- Volunteers
- 8,100 people
- Sponsor
- Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz
Acute Coronary Syndrome (ACS), High Bleeding Risk(HBR)
Safety and Efficacy of De-escalation Dual Antiplatelet Therapy After BioFreedom™ Stenting in ACS Patients With Moderate-to-high Ischemic and High Bleeding Risk
Patients with acute coronary syndrome (ACS) who have both high ischemic risk and high bleeding risk represent a challenging population following percutaneous coronary intervention (PCI), as prolonged dual antiplatelet therapy…
- Conditions
- Acute Coronary Syndrome (ACS), High Bleeding Risk(HBR), Coronary Artery Disease (CAD)
- Trial name
- NCT07374718
- Testing
- IVUS-guided BioFreedomTM Drug-Coated Stent Implantation + 1-Month DAPT Followed by 11-Month P2Y12 Inhibitor Monotherapy, Angiography-guided Conventional Drug-Eluting Stent Implantation + 12-Month Dual Antiplatelet Therapy (Aspirin + P2Y12 Inhibitor)
- Where
- China
- Volunteers
- 468 people
- Sponsor
- Shenyang Northern Hospital
Coronary Artery Disease
A Randomized Controlled Trial With Resolute Onyx in One Month Dual Antiplatelet Therapy (DAPT) for High-Bleeding Risk Patients
The purpose of this study is to evaluate the clinical safety and effectiveness of the Resolute Onyx stent in subjects deemed at high risk for bleeding and/or medically unsuitable for more than 1 month DAPT treatment receiving…
- Trial name
- Onyx ONE (NCT03344653)
- Testing
- Medtronic Resolute Onyx Zotarolimus-Eluting Coronary Stent System, Biosensors BioFreedom BA9 Drug Coated Coronary Stent
- Where
- 89 sites in Australia, Austria and 21 more
- Volunteers
- 2,000 people
- Sponsor
- Medtronic Vascular
Chronic Coronary Disease
One-Month DAPT in CABG Patients
The purpose of this study is to compare the effect of ticagrelor plus low-dose aspirin versus low-dose aspirin alone in patients with chronic coronary disease undergoing coronary artery bypass grafting.
- Trial name
- ODIN (NCT05997693)
- Testing
- Ticagrelor 90 MG, Low-dose aspirin
- Where
- 22 sites in United States, Austria and 4 more
- Volunteers
- 700 people
- Sponsor
- Weill Medical College of Cornell University
Coronary Artery Lesions
XIENCE 90: A Safety Evaluation of 3-month DAPT After XIENCE Implantation for HBR Patients.
XIENCE 90 study is a prospective, single arm, multi-center, open label trial to evaluate the safety of 3-month dual antiplatelet therapy (DAPT) in subjects at high risk of bleeding (HBR) undergoing percutaneous coronary…
- Trial name
- NCT03218787
- Testing
- XIENCE, DAPT
- Where
- 101 sites in United States
- Volunteers
- 2,047 people
- Sponsor
- Abbott Medical Devices
Coronary Artery Disease, Stents
P2Y12 Inhibitor Monotherapy Versus Extended DAPT in Patients Treated With Bioresorbable Scaffold
This study aimed to compare the efficacy and safety of P2Y12 inhibitor monotherapy versus extended dual antiplatelet therapy (DAPT) following 12-month of DAPT in patients undergoing percutaneous coronary intervention (PCI) with…
- Conditions
- Coronary Artery Disease, Stents, Atherosclerosis
- Trial name
- SMART-CHOICEII (NCT03119012)
- Testing
- Clopidogrel, Ticagrelor, Aspirin
- Where
- South Korea
- Volunteers
- 25 people
- Sponsor
- Samsung Medical Center
Coronary Arterial Disease (CAD), Percutaneous Coronary Intervention (PCI)
Efficacy and Safety of Shortening Dual Antiplatelet Therapy Duration with IVUS Guidance in PCI Patients
This study is designed to assess the efficacy and safety of de-escalating dual antiplatelet therapy (DAPT) at 1 month compared to the standard 12 months of therapy in patients undergoing percutaneous coronary intervention (PCI)…
- Conditions
- Coronary Arterial Disease (CAD), Percutaneous Coronary Intervention (PCI), Intravascular Ultrasound, Dual Antiplatelet Therapy
- Trial name
- SHORTDAPT (NCT06648720)
- Testing
- DAPT de-escalation
- Where
- Vietnam
- Volunteers
- 3,566 people
- Sponsor
- University Medical Center Ho Chi Minh City (UMC)
Peripheral Arterial Disease
Vascular Trial Associated Registry Pilot
The purpose of this investigator-initiated, multicenter, open label, randomized trial is to evaluate 1 month vs. 6 months of dual antiplatelet therapy (DAPT) in patients undergoing lower extremity endovascular revascularization.
- Trial name
- VSTAR-P (NCT07076082)
- Testing
- Clopidogrel (Plavix) Pharmacogenetic Test Reagents
- Where
- 2 sites in United States
- Volunteers
- 350 people
- Sponsor
- Corewell Health West
Coronary Artery Disease, Acute Coronary Syndrome
Bioresorbable Polymer-Coated EES in Patients at High Bleeding Risk Undergoing PCI Followed by 1-Month DAPT
Objective: To evaluate the safety of bioresorbable polymer-coated everolimus-eluting Synergy® stent followed by 1-month dual antiplatelet therapy in patients at high-bleeding risk.
- Trial name
- POEM (NCT03112707)
- Testing
- Aspirin, P2Y12 inhibitor
- Where
- Italy
- Volunteers
- 1,023 people
- Sponsor
- Humanitas Hospital, Italy
Coronary Artery Disease (CAD), Percutaneous Coronary Intervention (PCI)
Safety and Efficacy of Very Short DAPT in Older Patients Undergoing PCI
The goal of this clinical trial is to learn if reducing the duration of dual antiplatelet therapy (DAPT) after percutaneous coronary intervention (short treatment regimen, stopping aspirin at day 7) is as safe and efficient as…
- Conditions
- Coronary Artery Disease (CAD), Percutaneous Coronary Intervention (PCI), Antiplatelet Therapy, Elderly (People Aged 65 or More)
- Trial name
- SOLOPCI (NCT07164859)
- Testing
- short dual antiplatelet therapy (DAPT) duration, Standard DAPT duration
- Where
- France
- Volunteers
- 1,700 people
- Sponsor
- Vincent ROULE
Coronary Artery Disease
SAPT Versus DAPT in Incomplete Revascularization After CABG
The study aims to compare the efficacy of dual antiplatelet therapy (DAPT) over single antiplatelet therapy (SAPT) in patients with incomplete revascularization after coronary artery bypass graft surgery (CABG).
- Trial name
- SDAT-IRC (NCT03789916)
- Testing
- Ticagrelor, acetylsalicylic acid
- Where
- Italy
- Volunteers
- 800 people
- Sponsor
- Campus Bio-Medico University
Coronary Artery Disease, Percutaneous Coronary Intervention
Efficacy and Safety of 1-year Duration of DAPT After GENOSS® DES Implantation in Patients with Coronary Artery Disease According to the Complex Higher-risk Procedure
The objective of study is to evaluate the efficacy and safety of 1 year duration of DAPT after GENOSS® DES Implantation in patients with coronary artery disease according to the complex higher-risk (and indicated) procedure.
- Conditions
- Coronary Artery Disease, Percutaneous Coronary Intervention, Dual Antiplatelet Therapy
- Trial name
- DAPTLong (NCT06075433)
- Where
- South Korea
- Volunteers
- 1,000 people
- Sponsor
- Genoss Co., Ltd.
Coronary Artery Disease, Percutaneous Coronary Intervention
Ethnic Differences and the Ischemia/Bleeding Risk of DAPT Duration
this study is an individual patient level meta-analysis of randomized clinical trials, to evaluate the influence of ethnicity, to study whether the relative tradeoff between ischemia and bleeding is distinct by ethnicity.
- Conditions
- Coronary Artery Disease, Percutaneous Coronary Intervention, Dual Antiplatelet Therapy
- Trial name
- NCT03338335
- Testing
- prolonged DAPT
- Where
- South Korea
- Volunteers
- 16,000 people
- Sponsor
- Seoul National University Hospital
Myocardial Infarction, Coronary Artery Disease
Emulation of Randomized Clinical Trial in Cardiovascular Disease
Investigators are building an empirical evidence base for real world data through large-scale replication of randomized controlled trials.
- Trial name
- RCT-BigData (NCT06241833)
- Testing
- PPI
- Where
- South Korea
- Volunteers
- 118,420 people
- Sponsor
- Samsung Medical Center
Cardiovascular Diseases, Interventional Cardiology
Repetitive Assessement of PRECISE-DAPT Score
Patients treated with percutaneous coronary intervention (PCI) require dual antiplatelet therapy (DAPT). Preliminary assessment of the PRECISE-DAPT score is mandatory in order to assess the risk of bleeding while on DAPT.
- Trial name
- RE-SCORE (NCT03848572)
- Testing
- Repetitive assessment of PRECISE-DAPT score
- Where
- 2 sites in Italy
- Volunteers
- 500 people
- Sponsor
- University of Roma La Sapienza
Acute Coronary Syndrome (ACS), High Bleeding Risk (HBR)
Optimization and Validation of Quality Control Indicators for Coronary Revascularization Based on Antiplatelet Therapy
Study Purpose Coronary heart disease (CAD) is a leading global cause of death, with Acute Coronary Syndrome (ACS) as its acute and life-threatening subtype.
- Conditions
- Acute Coronary Syndrome (ACS), High Bleeding Risk (HBR), Coronary Artery Disease (CAD)
- Trial name
- NCT07354828
- Where
- China
- Volunteers
- 3,500 people
- Sponsor
- Shenyang Northern Hospital
Myocardial Infarction
Reduced Antithrombotic Strategy for High Bleeding Risk Patients With Myocardial Infarction
Rationale: Heart attacks are a major cause of death and result from coronary blood clots that require acute coronary intervention and antithrombotic drugs to restore blood flow and prevent new heart attacks.
- Trial name
- Dan-DAPT (NCT05262803)
- Testing
- CYP2C19*2/*3, Shorter DAPT duration
- Where
- 6 sites in Denmark
- Volunteers
- 2,808 people
- Sponsor
- Rikke Sorensen
Acute Coronary Syndrome
Rivaroxaban Combined With DAPT Versus DAPT Alone After Drug-coated Balloon Angioplasty
The target population of this interventional study was ACS patients with drug-coated balloons. The main discussion : 1.1 months of rivaroxaban combined with dual antiplatelet therapy compared with dual antiplatelet therapy alone…
- Trial name
- NCT05750758
- Testing
- rivaroxaban
- Where
- China
- Volunteers
- 140 people
- Sponsor
- Henan Institute of Cardiovascular Epidemiology
Ischemic Stroke, TIA
A REAl-life Study on Short-term DAPT in Patients With Ischemic Stroke or TIA
The REAl-life study on short-term Dual Antiplatelet treatment in Patients with ischemic stroke or Transient ischemic attack (READAPT) is an observational, multicenter, prospective study involving Italian centers.
- Trial name
- READAPT (NCT05476081)
- Testing
- Aspirin, Clopidogrel, Ticagrelor
- Where
- 127 sites in Italy
- Volunteers
- 2,239 people
- Sponsor
- University of L'Aquila